Miracle8989 Issues Voluntary Nationwide Recall of PremierZen Gold 7000, PremierZen Platinum 8000 and MaxxZEN Platinum 12000, Due to Presence of Undeclared Sildenafil and Tadalafil

If your email program has trouble displaying this email, view as a webpage. Miracle8989 Issues Voluntary Nationwide Recall of PremierZen Gold 7000, PremierZen Platinum 8000 and MaxxZEN Platinum 12000, Due to Presence of Undeclared Sildenafil and Tadalafil Irving, Texas, Miracle8989 is voluntarily recalling all lots PremierZen Gold 7000, PremierZen Platinum 8000 and MaxxZEN Platinum 12000, capsules to the consumer level. FDA analysis has found the products to contain undeclared sildenafil and tadalafil.  Sildenafil and Tadalafil are ingredients known as phosphodiesterase (PDE-5) inhibitors found in FDA approved products for the treatment of male erectile dysfunction.  The presence of Sildenafil and Tadalafil in PremierZen Gold 7000, PremierZen Platinum 8000 and MaxxZEN Platinum 12000 renders them unapproved drugs for which safety and efficacy have not been established and, therefore, subject to recall. Risk Statement: Consumers with underlying medical issues who take PremierZen Gold 7000, PremierZen Platinum 8000 and MaxxZEN Platinum 12000 with undeclared Sildenafil and Tadalafil may experience serious health risks.  For example, PDE-5 inhibitors may interact with nitrates found in some prescription drugs (such as nitroglycerin) lowering blood pressure to dangerous levels that may be life-threatening.  Consumers with diabetes, high blood pressure, or heart disease often take nitrates. To date, Ebay Seller Annie Cho has not received any reports of adverse events related to this recall. The tainted PremierZen Gold 7000, PremierZen Platinum 8000 and MaxxZEN Platinum 12000 products are marketed as dietary supplements for male sexual enhancement and is packaged in 1 count blister cards. The affected PremierZen Gold 7000, PremierZen Platinum 8000 and MaxxZEN Platinum 12000 include all lot numbers and all expiration dates.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA